BUZZ-Seres Therapeutics rises on 'breakthrough therapy' tag for blood infection treatment

Reuters12-09
BUZZ-Seres <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises on 'breakthrough therapy' tag for blood infection treatment

** Shares of drug developer Seres Therapeutics MCRB.O rise 14.1% to 93 cents premarket

** Says the U.S. FDA has granted "Breakthrough Therapy" designation to its experimental treatment, SER-155

** The treatment helps reduce bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant to treat various types of blood cancers

** The transplant uses blood stem cells from a donor to replace bone marrow that's not producing enough healthy blood cells

** SER-155 was well-tolerated with no treatment-related serious adverse events in an early-stage study - MCRB

** The FDA's tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need

** Co is actively seeking a partner to provide financial resources and other capabilities to support its goal to maximize the SER-155 program opportunity

** Up to last close, stock down 41.2% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment